Trial · NCT03350347
A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects
NCT03350347, Phase 3, Completed, Bayer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects. Trials, record NCT03350347. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03350347
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects
- NCT number
- NCT03350347
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 164 participants, actual
- Lead sponsor
- Bayer
- Conditions
- Anemia, Renal Insufficiency, Chronic
- Interventions
- Molidustat (BAY85-3934), Darbepoetin alfa
- First posted
- 2017-11-22
- Last updated
- 2021-01-29
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Hb (Hemoglobin) level | From week 30 to 36 | |
| Primary | Change in hemoglobin level from baseline to the average during the evaluation period | Baseline and week 30 to 36 | |
| Secondary | Responder rate: proportion of responders among the subjects | From week 30 to 36 | Responder is defined as meeting all of the following criteria: (i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment |
| Secondary | Proportion of subjects who meet each component of the response | From week 30 to 36 | Response: (i) Mean of the Hb levels in the target range (ii) ≥ 50% of the Hb levels in the target range (iii) No rescue treatment |
| Secondary | Hb level | Baseline and up to 52 weeks | |
| Secondary | Change in Hb level | Baseline and up to 52 weeks | |
| Secondary | Proportion of subjects whose mean hemoglobin levels are in the target range during the evaluation period | From week 30 to 36 | |
| Secondary | Proportion of subjects whose mean hemoglobin levels are above the target range during the evaluation period | From week 30 to 36 | |
| Secondary | Proportion of subjects whose mean hemoglobin levels are below the target range during the evaluation period | From week 30 to 36 | |
| Secondary | Proportion of subjects whose hemoglobin levels are in the target range | Up to 52 weeks |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03350347
GET https://conductscience.org/api/trials/v1/NCT03350347/registered